Poster – Evaluation of the Galileo™ Pathogen Solution Next-Generation Sequencing Pipeline for the Identification and Quantification of DNA Viruses in Transplant Patients

Feb 11, 2020

NGS-based metagenomics in the clinical virology laboratory

Poster Presentation at the Association for Molecular Pathology Conference 2018

Evaluation of the Galileo™ Pathogen Solution Next-Generation Sequencing Pipeline for the Identification and Quantification of DNA Viruses in Transplant Patients

This poster was presented at the Association for Molecular Pathology Conference, which took place in San Antonio Texas in November 2018 by Dr. Meredith L. Carpenter, Director Of Assay Research & Development at Arc Bio.

Abstract:

“Solid organ and hematopoietic stem cell transplant recipients are uniquely susceptible to infections, often with increased severity, due to a number of common and opportunistic viruses. Specifically, viral infections including cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV), human herpesvirus-6 (HHV6) and human Adenovirus (ADV) can cause outcomes ranging from severe illness to transplant failure and even death.

There are only handful of commercial assays available for detecting/quantifying CMV, with the remainder of assays available as either ASRs or LDTs. These tests measure the presence of and/or viral load of the target virus, enabling clinical assessment of progression and the efficacy of treatment. However, all of these tests are run individually, and they fail to detect non-targeted co-infections, which are common in immunocompromised patients.

Next-generation sequencing (NGS) has the potential to enable clinicians to determine the presence and abundance of transplant-related viruses with unprecedented precision, as well as identify co-infections in an unbiased manner. Sequencing of clinical samples can reveal pathogens that targeted investigations miss, including un-culturable or closely related species, all in a single test.”

In this presentation you will learn:

What is NGS-based metagenomics (mNGS) is and how it can be applied to pathogen detection
How mNGS compares with and improves upon qPCR as a detection platform
What the mNGS workflow looks like when deployed in your laboratory
Why deploying mNGS into your laboratory makes sense
How Arc Bio has approached mNGS with its Galileo™ platform

TPx_Poster_AMP_Layout_103018

For research use only. Not for use in diagnostics or diagnostic procedures.

Do you have a Question about Galileo™

We’d love to hear from you! Do you have any questions about the Galileo™ Platform?

Poster – Evaluation of a Next-Generation Sequencing Metagenomics Assay to Detect and Quantify DNA Viruses in Plasma from Transplant Patients

Jun 1, 2019

Enabling NGS-based metagenomics in the clinical virology laboratory

Poster Presentation given at the Clinical Virology Symposium 2019

Learn more about Galileo™

Evaluation of a Next-Generation Sequencing Metagenomics Assay to Detect and Quantify DNA Viruses in Plasma from Transplant Patients

This poster was presented at the Clinical Virology Symposium on May 6th, 2019 by Dr. Soya S. Sam, a member of Dr. Angela Caliendo team from the Warren Alpert School of Medicine at Brown University.

Abstract:

“Viral infections are major causes of morbidity and mortality in solid organ and hematopoietic stem cell transplant patients Cytomegalovirus (CMV), Epstein–Barr virus (EBV) and BK virus (BKV) are among the most common infections after allogeneic transplantations and are individually tested using qPCR assays.

Metagenomics based on shotgun next-generation sequencing allows an unbiased approach for the detection of nearly all potential pathogens in a single assay. The objective of the study was to evaluate the performance characteristics of the Galillo™-Transplant assay by comparing with standard-of-care qPCR assays using viremic plasma from transplant patients.”

In this presentation you will learn:

What is NGS-based metagenomics (mNGS) is and how it can be applied to pathogen detection
How mNGS compares with and improves upon qPCR as a detection platform
What the mNGS workflow looks like when deployed in your laboratory
Why deploying mNGS into your laboratory makes sense
How Arc Bio has approached mNGS with its Galileo™ platform

Brown Poster

For research use only. Not for use in diagnostics or diagnostic procedures.

Do you have a Question about Galileo™

We’d love to hear from you! Do you have any questions about the Galileo™ Platform?

Poster – Performance of an NGS-based metagenomics assay to simultaneously detect and quantify multiple DNA viruses

May 6, 2019

Enabling NGS-based metagenomics in the clinical virology laboratory

Poster Presentation given at the Clinical Virology Symposium 2019

Learn more about Galileo™

Performance of an NGS-based metagenomics assay to simultaneously detect and quantify multiple DNA viruses

This poster was presented at the Clinical Virology Symposium on May 6th, 2019 by Dr. Julianne Brown, Clinical Scientist in the Virology Department at Great Ormond Street Hospital for Children NHS Foundation Trust in London.

Abstract:

“Viral infections in solid organ and bone marrow transplant recipients can cause outcomes ranging from severe illness to transplant failure and even death. Current diagnostic assays use PCR to measure qualitative and quantitative presence of a target virus enabling clinical assessment of progression and the efficacy of treatment, however, these require multiple reactions and fail to detect non-targeted co-infections, which are common in immunocompromised patients.

Metagenomic next-generation sequencing (mNGS) has the potential to determine the presence and abundance of transplant-related viruses, as well as identify co-infections, in an unbiased manner.”

In this presentation you will learn:

What is NGS-based metagenomics (mNGS) is and how it can be applied to pathogen detection
How mNGS compares with and improves upon qPCR as a detection platform
What the mNGS workflow looks like when deployed in your laboratory
Why deploying mNGS into your laboratory makes sense

GOSH poster

For research use only. Not for use in diagnostics or diagnostic procedures.

Do you have a Question about Galileo™

We’d love to hear from you! Do you have any questions about the Galileo™ Platform?

Poster – Megaplasmids on the rise: combining sequencing approaches to fully resolve a carbapenemase – encoding plasmid in a novel Pseudomonas species

Apr 24, 2019

Detection of Antimicrobial Resistance

Poster Presentation at the 9th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2019)

Learn more about Galileo™

Megaplasmids on the rise: combining sequencing approaches to fully resolve a carbapenemase – encoding plasmid in a novel Pseudomonas species

This poster was presented at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which took place in Amsterdam in April 2019 by Dr. João Botelho at UCIBIO/REQUIMTE, Laboratório de Microbiologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.

Abstract:

“Horizontal transfer of plasmids plays a pivotal role in the dissemination of antibiotic resistance genes and the emergence of multidrug-resistant bacteria. Sequencing of plasmids is thus paramount for the success of accurate epidemiological tracking strategies in the hospital setting and routine surveillance.

Fully resolving plasmids using short-read sequencing technologies remains challenging due to the presence of numerous long repeated regions, and currently, the most accurate approach to assemble these plasmids is to use a combination of short-read and long-read methods.

Here, we combined Nanopore and Illumina sequencing to fully assemble a carbapenemase-encoding megaplasmid carried by an isolate belonging to a putative novel pseudomonas species.”

posterECCMID2019

For research use only. Not for use in diagnostics or diagnostic procedures.

Do you have a Question about Galileo™

We’d love to hear from you! Do you have any questions about the Galileo™ Platform?